Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Venus RemediesBOM:526953 -1.21%51 EV-to-EBITDA is 12.21 as of Sep. 05, 2026, which is 144% above its 10-year median of 5.01. GuruFocus rates BOM:526953 with a GF Score™ of 51/100 and a GF Value™ of ₹526.54 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 726 Drug Manufacturers companies, Venus Remedies ranks better than 53.72% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Venus Remedies's enterprise value is ₹21,715 Mil.
Venus Remedies's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹1,779 Mil. Therefore, Venus Remedies's EV-to-EBITDA for today is 12.21.
The historical rank and industry rank for Venus Remedies's EV-to-EBITDA or its related term are showing as below:
BOM:526953'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0.99 Med: 5.01 Max: 15.73
Current: 12.21
During the past 13 years, the highest EV-to-EBITDA of Venus Remedies was 15.73. The lowest was 0.99. And the median was 5.01.
BOM:526953's EV-to-EBITDA is ranked better than 53.72% of 726
companies
in the Drug Manufacturers industry
Industry Median: 13.55
vs BOM:526953: 12.21
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Venus Remedies's PE Ratio (TTM) for today is calculated as:
Venus Remedies's share price for today is ₹1689.25.
Venus Remedies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹86.910.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Venus Remedies's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Venus Remedies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Venus Remedies EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Venus Remedies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Venus Remedies's EV-to-EBITDA falls into.
Venus Remedies's current Enterprise Value is ₹21,715 Mil.
Venus Remedies's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,779 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Venus Remedies (BOM:526953) has a EV-to-EBITDA of 12.21 as of Sep. 05, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Venus Remedies. This is 144% above median its historical median of 5.01. Over the past decade, Venus Remedies' EV-to-EBITDA has ranged from 0.99 to 15.73. According to the industry distribution chart, Venus Remedies ranks #336 out of 726 companies in the Drug Manufacturers industry, placing it in the top 46.3%.
Is Venus Remedies' EV-to-EBITDA too high?
Venus Remedies' current EV-to-EBITDA of 12.21 is 144% above median its 10-year median of 5.01. Over the past 10 years, this metric has ranged from a low of 0.99 to a high of 15.73. The Drug Manufacturers industry median EV-to-EBITDA is 13.55. Venus Remedies' value of 12.21 is 9.9% below this industry median. Based on the distribution chart, Venus Remedies ranks #336 out of 726 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Venus Remedies has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Venus Remedies' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Venus Remedies ranks #336 out of 726 companies for EV-to-EBITDA. This puts Venus Remedies in the upper half of its industry. The industry median EV-to-EBITDA is 13.55. Venus Remedies' value of 12.21 is 9.9% below this benchmark. Historically, Venus Remedies' own EV-to-EBITDA has ranged from 0.99 to 15.73 over the past decade. While the company's 10-year median is 5.01 vs. the industry median of 13.55, Venus Remedies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.55, based on 726 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Venus Remedies's current EV-to-EBITDA of 12.21 is 9.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Venus Remedies. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Venus Remedies's current EV-to-EBITDA is 12.21, which is 144% above median its own 10-year median of 5.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Remedies stock overvalued right now?
Based on GuruFocus' analysis, Venus Remedies (BOM:526953) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹526.54, compared to a current price of ₹1,689.25 — trading 220.8% above its estimated fair value. The current EV-to-EBITDA is 12.21, which is 144% above median its 10-year median of 5.01 and 9.9% below the Drug Manufacturers industry median of 13.55. Venus Remedies' overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Venus Remedies (BOM:526953), the current EV-to-EBITDA is 12.21 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Venus Remedies (BOM:526953) Overvalued in 2026?
Based on GuruFocus' analysis, Venus Remedies stock appears to be overvalued.
The current stock price of ₹1,689.25 is trading 220.8% above its estimated GF Value™ of ₹526.54.
GuruFocus considers Venus Remedies to be Significantly Overvalued.
Key valuation signals for BOM:526953:
EV-to-EBITDA: 12.21 (144% above median its 10-year median of 5.01)
GF Value™: ₹526.54 vs. price of ₹1,689.25 (220.8% above fair value)
Industry Position: 9.9% below the Drug Manufacturers median (#336 of 726)
No single metric tells the full story. See the BOM:526953 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Venus Remedies Ltd is an Indian drug manufacturer. It is engaged in manufacturing and trading pharmaceutical products. The company produces biologically active food supplements which include food supplements are natural complexes containing minerals, vitamins, dietary fibers, extracts of medicinal herbs, amino acids and others.
51GF Score
Get the complete analysis for BOM:526953
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:526953 has been successfully added to your 
